Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178722 · ClinicalTrials.gov registry record · Phase 1
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 444
- Enrollment target
NCT02178722 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 444 participants.
The verdict
NCT02178722, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 444 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
Interventions
- DRUG MK-3475
- DRUG INCB024360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2014-07-17 |
| Est. Completion | 2020-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02178722
The ClinicalTrials.gov registry entry for NCT02178722 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MK-3475 is the first listed.
NCT02178722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02178722 about?
NCT02178722 is a clinical study titled "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers". The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
What is the current status of trial NCT02178722?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 444 participants. The study started on 2014-07-17. Estimated completion is 2020-11-06.
What interventions are being tested in trial NCT02178722?
The interventions under investigation include: MK-3475 (DRUG), INCB024360 (DRUG).
Who is sponsoring clinical trial NCT02178722?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.